Physician profile
Henry Su
NPI 1902033913
$4,933.87
in general payments reported to CMS, 2019-2025
19 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $484 · 2021: $1,230 · 2022: $1,456 · 2023: $225 · 2024: $125 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479 · Education: $56.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.20 |
| Education | $56.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,064.90 | 2019-2025 | Apretude, Rukobia, Dovato |
| Merck Sharp & Dohme LLC | $586.72 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $584.19 | 2019-2023 | |
| Janssen Biotech, INC. | $409.88 | 2019-2022 | |
| Shionogi INC | $400.98 | 2020-2025 | Fetroja |
| Astellas Pharma US INC | $379.14 | 2019-2021 | |
| Abbvie INC. | $343.16 | 2019-2022 | |
| Emd Serono, INC. | $297.17 | 2019-2022 | |
| Allergan, INC. | $170.46 | 2019-2020 | |
| Janssen Products, LP | $128.99 | 2019-2021 | |
| Melinta Therapeutics, LLC | $105.27 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $86.93 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $85.44 | 2021-2023 | |
| Insmed, INC. | $70.83 | 2019-2024 | Arikayce |
| Napo Pharmaceuticals INC | $64.85 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $63.85 | 2019-2022 | |
| Glaxosmithkline, LLC. | $52.33 | 2022 | |
| Mylan Specialty L.P. | $21.02 | 2019 | |
| Nabriva Therapeutics, Plc | $17.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.